YOU ARE HERE >  Moneycontrol Markets > Announcements PharmaceuticalsAnnouncement - AstraZeneca

26th-Sep-2021 17:43Source: BSE

AstraZeneca Pharma - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 From The Drugs Controller General Of India For Selumetinib 10 Mg & 25 Mg Capsule

This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule.

Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).

The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.